121 related articles for article (PubMed ID: 35675759)
1. A polymorphic variant in telomere maintenance is associated with worrisome features and high-risk stigmata development in IPMNs.
Giaccherini M; Gentiluomo M; Arcidiacono PG; Falconi M; Testoni SGG; Apadula L; Lauri G; Di Franco G; Fatucchi LM; Petrone MC; Corradi C; Crippa S; Morelli L; Capurso G; Campa D
Carcinogenesis; 2022 Sep; 43(8):728-735. PubMed ID: 35675759
[TBL] [Abstract][Full Text] [Related]
2. Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis.
Crippa S; Bassi C; Salvia R; Malleo G; Marchegiani G; Rebours V; Levy P; Partelli S; Suleiman SL; Banks PA; Ahmed N; Chari ST; Fernández-Del Castillo C; Falconi M
Gut; 2017 Mar; 66(3):495-506. PubMed ID: 26743012
[TBL] [Abstract][Full Text] [Related]
3. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study.
Campa D; Matarazzi M; Greenhalf W; Bijlsma M; Saum KU; Pasquali C; van Laarhoven H; Szentesi A; Federici F; Vodicka P; Funel N; Pezzilli R; Bueno-de-Mesquita HB; Vodickova L; Basso D; Obazee O; Hackert T; Soucek P; Cuk K; Kaiser J; Sperti C; Lovecek M; Capurso G; Mohelnikova-Duchonova B; Khaw KT; König AK; Kupcinskas J; Kaaks R; Bambi F; Archibugi L; Mambrini A; Cavestro GM; Landi S; Hegyi P; Izbicki JR; Gioffreda D; Zambon CF; Tavano F; Talar-Wojnarowska R; Jamroziak K; Key TJ; Fave GD; Strobel O; Jonaitis L; Andriulli A; Lawlor RT; Pirozzi F; Katzke V; Valsuani C; Vashist YK; Brenner H; Canzian F
Int J Cancer; 2019 Mar; 144(6):1275-1283. PubMed ID: 30325019
[TBL] [Abstract][Full Text] [Related]
4. Histopathological evaluation of resected intraductal papillary mucinous neoplasms reveals distinct patterns of invasion in associated carcinomas.
Rift CV; Lund EL; Scheie D; Hansen CP; Hasselby JP
Hum Pathol; 2021 Jul; 113():47-58. PubMed ID: 33915115
[TBL] [Abstract][Full Text] [Related]
5. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
6. Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasm progression.
Gentiluomo M; Corradi C; Arcidiacono PG; Crippa S; Falconi M; Belfiori G; Farinella R; Apadula L; Lauri G; Bina N; Rizzato C; Canzian F; Morelli L; Capurso G; Campa D
Front Oncol; 2023; 13():1172606. PubMed ID: 37346070
[TBL] [Abstract][Full Text] [Related]
7. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
[TBL] [Abstract][Full Text] [Related]
8. Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights.
Mas L; Lupinacci RM; Cros J; Bachet JB; Coulet F; Svrcek M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201897
[TBL] [Abstract][Full Text] [Related]
9. Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception.
Hernandez S; Parra ER; Uraoka N; Tang X; Shen Y; Qiao W; Jiang M; Zhang S; Mino B; Lu W; Pandurengan R; Haymaker C; Affolter K; Scaife CL; Yip-Schneider M; Schmidt CM; Firpo MA; Mulvihill SJ; Koay EJ; Wang H; Wistuba II; Maitra A; Solis LM; Sen S
Clin Cancer Res; 2022 May; 28(9):1938-1947. PubMed ID: 35491652
[TBL] [Abstract][Full Text] [Related]
10. Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project.
Semaan A; Bernard V; Wong J; Makino Y; Swartzlander DB; Rajapakshe KI; Lee JJ; Officer A; Schmidt CM; Wu HH; Scaife CL; Affolter KE; Nachmanson D; Firpo MA; Yip-Schneider M; Lowy AM; Harismendy O; Sen S; Maitra A; Jakubek YA; Guerrero PA
Cancer Res Commun; 2023 Oct; 3(10):2062-2073. PubMed ID: 37721516
[TBL] [Abstract][Full Text] [Related]
11. Does a family history of pancreatic ductal adenocarcinoma and cyst size influence the follow-up strategy for intraductal papillary mucinous neoplasms of the pancreas?
Mandai K; Uno K; Yasuda K
Pancreas; 2014 Aug; 43(6):917-21. PubMed ID: 24743378
[TBL] [Abstract][Full Text] [Related]
12. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M
Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484
[TBL] [Abstract][Full Text] [Related]
13. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
[TBL] [Abstract][Full Text] [Related]
15. Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression.
Overbeek KA; Alblas M; Gausman V; Kandel P; Schweber AB; Brooks C; Van Riet PA; Wallace MB; Gonda TA; Cahen DL; Bruno MJ
Aliment Pharmacol Ther; 2019 Oct; 50(7):789-799. PubMed ID: 31429105
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatic Analysis and Integration of Transcriptome and Proteome Results Identify Key Coding and Noncoding Genes Predicting Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Saha B; Chhatriya B; Pramanick S; Goswami S
Biomed Res Int; 2021; 2021():1056622. PubMed ID: 34790815
[TBL] [Abstract][Full Text] [Related]
17. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
18. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
[TBL] [Abstract][Full Text] [Related]
19. Single-cell RNA sequencing highlights epithelial and microenvironmental heterogeneity in malignant progression of pancreatic ductal adenocarcinoma.
Li J; Wei T; Ma K; Zhang J; Lu J; Zhao J; Huang J; Zeng T; Xie Y; Liang Y; Li X; Zhang Q; Liang T
Cancer Lett; 2024 Mar; 584():216607. PubMed ID: 38246225
[TBL] [Abstract][Full Text] [Related]
20. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
